|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The upregulated phosphorylation of IRS-1 (S307), down-regulated phosphorylation of PI3Kp85α, Akt, and FoxO1a were significantly reversed by LWDH Pills (3.6 g kg<sup>-1</sup>·day<sup>-1</sup>) in PCOS-IR rats with up-regulated mRNA levels of FSHR and Cyp19a1 in ovary.
|
31185267 |
2020 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therefore, TSIIA revises the balance of androgen and estrogen by rescuing the reduced expression of FSHR and aromatase, thus attenuating murine PCOS.
|
30988730 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
AKR1C3 is implicated in the production of androgens in castration-resistant prostate cancer (CRPC) and polycystic ovarian syndrome; and is implicated in the production of aromatase substrates in breast cancer.
|
30012349 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Ovulation can be restored in women with PCOS using letrozole (an aromatase inhibitor), clomifene citrate (an oestrogen antagonist) or exogenous gonadotrophin administration.
|
31296604 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that insulin may contribute to AMH elevation in PCOS and that AMH counteracts insulin-promoted aromatase expression in granulosa cells.
|
30477916 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
AMH increased mRNA levels of aromatase (P < 0.05, one-way ANOVA) and FSHR (P < 0.0001, one-way ANOVA) in hGLCs from women with PCOM, but not from normal cells or PCOS (normal n = 7, PCOM n = 5, PCOS n = 4).
|
31735954 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of FSHR (P < 0.05), AR (P < 0.05), and CYP11A1 (P < 0.05) was lower, and expression of CYP19A1 (P < 0.05), STAR (P < 0.05), HSD3B2 (P = NS), and INHBA (P < 0.05) was higher in PCO GCs.
|
31276164 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These mechanisms may be involved in the enhanced aromatase transcription during ovarian stimulation in PCOS patients.
|
31360184 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MiR-29a regulates the proliferation, aromatase expression, and estradiol biosynthesis of human granulosa cells in polycystic ovary syndrome.
|
31421163 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
We previously developed a pubertal mouse model using the aromatase inhibitor, letrozole, which recapitulates many of the reproductive and metabolic features of PCOS.
|
30871463 |
2019 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
As a nonsteroidal aromatase inhibitor, letrozole blocks conversion of testosterone to estrogen and subsequently induces PCOS phenomenon.
|
30287740 |
2018 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated that continuous exposure to the aromatase inhibitor letrozole (LET) in mice produces many hallmarks of PCOS, including elevated testosterone (T) and luteinizing hormone, anovulation, and obesity.
|
29471436 |
2018 |
|
Polycystic Ovary Syndrome
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Variations of CYP19A1 were not statistically significant with PCOS.
|
29564739 |
2018 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study demonstrate a crucial role for AKAP95 in CYP19A1 expression and oestrogen synthesis in hLGCs, which implies that AKAP95 may be involved in the pathogenesis of PCOS.
|
29397057 |
2018 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
To evaluate the effectiveness and safety of aromatase inhibitors for subfertile women with anovulatory PCOS for ovulation induction followed by timed intercourse or intrauterine insemination (IUI).
|
29797697 |
2018 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Treatment with soy isoflavones exerts beneficial effects in PCOS rats (with decreased aromatase activity) which might be due to their ability to decrease testosterone concentration in the peripheral blood.
|
27927075 |
2017 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
Letrozole is a nonsteroidal aromatase inhibitor that is used in experimental research to induce PCOS.
|
28875319 |
2017 |
|
Polycystic Ovary Syndrome
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings indicated that the CYP19 alleles rs727479A/C and rs700519C/T might be associated with the pregnancy outcome after ART in patients with PCOS.
|
29050673 |
2017 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
AMHR-II: anti-müllerian hormone receptor-II; 3β-HSD: 3β-hydroxysteroid dehydrogenase; Cyp11a1: Cytochrome P450 Family 11 Subfamily A Member 1; Cyp19a1: cytochrome P450 aromatase; DHEA: dehydroepiandrosterone; FSH: follicle stimulating hormone; FSHR: follicle stimulating hormone receptor; IVF: in vitro fertilization; 25OHD: 25-hydroxy vitamin D; OHSS: ovarian hyperstimulation syndrome; PCOS: polycystic ovarian syndrome; P450scc: P450 side-chain cleavage enzyme; StAR: steroidogenic acute regulatory protein; VDRs: vitamin D receptors.
|
28345956 |
2017 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These findings provide evidence that increased BPA concentration in the follicular fluid of PCOS patients may play an important role in its pathogenesis by attenuating the expression of aromatase in granulosa cells.
|
27187585 |
2017 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a rat model of PCOS induced by the inhibition of P450 aromatase, low-frequency electroacupuncture increased low-density lipoprotein-cholesterol but did not improve the insulin resistance or the adipose tissue dysfunction, suggesting that a balance of sex steroids is needed to restore the metabolic function in this rat model of PCOS.
|
27790765 |
2017 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the hyperandrogenic follicular environment may be a key hazardous factor leading to the down-regulation of aromatase in PCOS.
|
26199450 |
2015 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
There is an increased expression of aromatase P450 in PCOS patient endometrium.
|
25374239 |
2014 |
|
Polycystic Ovary Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that testosterone treatment of myotubes increases the aromatase and androgen receptor gene expression without affecting insulin sensitivity and if testosterone is implicated in muscular insulin resistance in PCOS, this is by and indirect mechanism.
|
25130462 |
2014 |
|
Polycystic Ovary Syndrome
|
0.600 |
Biomarker
|
disease |
RGD |
In female rats, continuous administration of letrozole, a nonsteroidal inhibitor of P450 aromatase, at 400 μg/d starting before puberty induces hyperandrogenemia and reproductive abnormalities similar to those in women with PCOS.
|
23183180 |
2013 |